The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review
Open accessPublished version of a preprint
Abstract
Importance High-grade gliomas (HGG) are the most aggressive and common malignant brain tumors in adults. They have a dismally fatal prognosis. Even if gross total resection of the enhancing tumor is achieved, inevitably, invading tumor cells that are indistinguishable to the un-aided eye are left behind, which eventually leads to tumor recurrence. 5-aminolevulinic acid (5-ALA) is an increasingly utilized intraoperative fluorescent imaging agent for patients with HGG. It enhances visualization of HGG tissue. Despite early promising randomized clinical trial data suggesting a survival benefit for 5-ALA-guided surgery, the growing body of literature must be analyzed to confirm efficacy on patient outcomes. Objective To perform a systematic review of the literature to evaluate whether there is a beneficial effect upon survival and extent of resection due to the utilization of 5-ALA in HGG surgery. Evidence review Literature regarding 5-ALA usage in HGG surgery was reviewed according to the PRISMA guidelines. Two databases, PubMed and SCOPUS, were searched for assorted combinations of the keywords "5-ALA," "high-grade glioma," "5-aminolevulinic acid," and "resection" in July 2020 for case reports and retrospective, prospective, and randomized clinical trials assessing and analyzing 5-ALA intraoperative use in patients with HGG. Entailed studies on PubMed and SCOPUS were found for screening using a snowball search technique upon the initially searched papers. Systematic reviews and meta-analyses were excluded from our PRISMA table. Findings 3756 previously published studies were screened, 536 of which were further evaluated, and ultimately 45 were included in our systematic review. There were no date restrictions on the screened publications. Our literature search was finalized on July 16, 2020. We found an observed increase in the overall survival (OS) and progression-free survival (PFS) of the 5-ALA group compared to the white light group, as well as an observed increase in the OS and PFS of complete resections compared to incomplete resections. Of the studies that directly compared the use of 5-ALA to white light (13 of the total analyzed 45, or 28.9%), 5-ALA lead to a better PFS and OS in 88.4 and 67.5% of patients, respectively. When the studies that reported postoperative neurologic outcomes of surgeries using 5-ALA vs. white light were analyzed, 42.2% of subjects demonstrated 5-ALA use was associated with less post-op neurological deficits, whereas 34.5% demonstrated no difference between 5-ALA and without. 23.3% of studies showed that intraoperative 5-ALA guided surgeries lead to more post-op neurological deficits. Conclusions and relevance Utilization of 5-ALA was found to be associated with a greater extent of resection in HGG surgeries, as well as longer OS and PFS. Postop neurologic deficit rates were mixed and inconclusive when comparing 5-ALA groups to white light groups. 5-ALA is a useful surgical adjunct for resection of HGG when patient safety is preserved.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, due to the invasive growth of high-grade glioma cells and the similarity in appearance between tumor and surrounding normal tissues, glioma surgery under conventional white light illumination often leaves behind viable tumor tissue, resulting in subsequent disease recurrence [46].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [46]
Citations
Cites
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Lacroix, M., Abi-Said, D., Fourney, D. R., V, Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E. C., et al. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,162
An extent of resection threshold for newly diagnosed glioblastomas
Sanai, N., Polley, M. C., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,685
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
Stummer, W., Reulen, H. J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J., Rohde, V., Oppel, F., Turowski, B., Woiciechowsky, C., et al. (2008) · Neurosurgery · doi:10.1227/01.neu.0000317304.31579.17 · Cited by 1,071
Stummer, W., Novotny, A., Stepp, H., Goetz, C., Bise, K., & Reulen, H. J. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.93.6.1003 · Cited by 881
PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts
Beller, E. M., Glasziou, P. P., Altman, D. G., Hopewell, S., Bastian, H., Chalmers, I., Gøtzsche, P. C., Lasserson, T., Tovey, D., & for the PRISMA for Abstracts Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001419 · Cited by 706
5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
Pichlmeier, U., Bink, A., Schackert, G., & Stummer, W. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-052 · Cited by 331
Stummer, W., Tonn, J., Mehdorn, H. M., Nestler, U., Franz, K., Goetz, C., Bink, A., & Pichlmeier, U. (2010) · Journal of neurosurgery · doi:10.3171/2010.3.jns097 · Cited by 313
Eljamel, S., Goodman, C., & Moseley, H. (2007) · Lasers in Medical Science · doi:10.1007/s10103-007-0494-2 · Cited by 287
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–105 of 105
Mwibwe, L. M., Chang, T., Zong, Y., Quan, Y., Wu, Y., Liao, J., Li, Y., Fang, Y., Zhang, L., Shu, Q., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834752
Passive Intraoperative Tumor Mapping Using Electrocorticography
Wu, Y., Chang, T., Chen, S., Schalk, G., Jiang, N., Mao, Q., Yang, Y., & He, J. (2026) · Springer briefs in electrical and computer engineering · doi:10.1007/978-3-032-25828-1_7
Chibbaro, S., Mallereau, C.-H., Ganau, M., Zaed, I., Dannhoff, G., Todeschi, J., Alfieri, A., Haemmerli, J., Cardia, A., Bruno, C., et al. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05769-z
Short communication: Fluorescence preservation of protoporphyrin IX in fresh frozen glioma tissue
Demetz, M., Buckley, K., Miller-Michlits, A., Miller-Michlits, Y., Krigers, A., Kerschbaumer, J., Thomé, C., Wöehrer, A., & Freyschlag, C. F. (2026) · Brain and Spine · doi:10.1016/j.bas.2026.106665
Toyota, P. R., Liu, E., Gould, L., Norton, J., Slough, K., Appendino, J. P., Persad, A. R. L., & Hnenny, L. P. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.112368
Metadata
- Authors
- Eatz, T. A., Eichberg, D. G., Lu, V. M., Di, L., Komotar, R. J., & Ivan, M. E.
- Affiliations
- University of Miami (US)
- Corresponding author
- Ivan, Michael E.
- Venue
- Journal of Neuro-Oncology
- Published
- 2022-01
- Volume
- 156
- Issue
- 2
- Pages
- 233-256
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W4226077183
- Cited by
- 93
- References
- 54
- Citations by year
- 2026: 15 · 2025: 25 · 2024: 18 · 2023: 23 · 2022: 12
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- 5-aminolevulinic acid, fluorescence-guided surgery, high-grade glioma, extent of resection, overall survival, progression-free survival, recurrent glioma, postoperative neurological outcome, brain tumor surgery, prognostic factors
- MeSH terms
- Brain Neoplasms, Glioma, Humans, Treatment Outcome, Neurosurgical Procedures, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review